Medindia

X

Mithra Research LLC Initiates Coverage on Wound Management Technologies, Inc.

Wednesday, July 28, 2010 Research News J E 4
Advertisement


FORT WORTH, Texas, July 28 Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) announced today that Mithra Research LLC, a respected independent equity research boutique, has initiated research coverage on the Company with a "Speculative Buy" rating and a target price of $3.75.

Gary Goldstein, President of Mithra Research, was quoted as saying, "We are pleased to initiate coverage on Wound Management Technologies at this exciting time as the Company transitions from development to commercialization. With Wound Management Technologies' truly game-changing product line, CellerateRX®, gaining traction in the market place, we believe it is only a matter of time before CellerateRX® is recognized as a must-have for 'best practices' in wound healing. Further, with the Company's complementary product offerings on track to come to market in the near term, we believe we are at the beginning of what will be an impressive long term investment."

Deborah Jenkins Hutchinson, President of WNDM, stated that "Our Company is emerging from its development stages and is actively growing and expanding our customer bases worldwide. We feel that Mithra Research's coverage of WNDM comes at an ideal time for us and our investors in this growth stage."

To receive current news and information about Wound Management Technologies and its companies, subscribe to join the WNDM email distribution list on the home page or investor page of www.wmgtech.com.

For Wound Management Technologies Shareholder Information please call 817-820-7077 or go to http://www.wmgtech.com.

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc.'s primary focus is the distribution of its unique, patented collagen product, CellerateRx®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes. Over the past 2 years Wound Management has focused on developing evidenced-based studies on CellerateRX and gaining physician awareness by participation in key industry conferences. Now Wound Management is focused on expanding sales through partnerships and contracted independent representatives. Wound Management has other advanced biotech products in development for bone wax, bone void fillers and shingles pain reduction as well as a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com, http://www.celleraterx.com, and http://www.secureehealth.com .

About Mithra Research LLC

Mithra Research LLC provides quality independent fundamental research to institutional clients. The boutique's research is focused on locating unknown, underfollowed, turnaround, or mis-priced opportunities. Mithra Research works in association with Sound Securities LLC, a superior execution-only trading firm. To view Mithra Research's coverage initiation on Wound Management Technologies, Inc. please contact Mithra Research LLC at Research@MithraResearch.com.

Safe Harbor Statement:

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

For Further Information:

Shareholder Relations-Communications (817)820-7077

SOURCE Wound Management Technologies, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Simbionix Continues its Global Expansion
S
Accuray Incorporated to Report Financial Results f...